Harvard Bioscience Reports 11.1% Revenue Growth in Q2 2026 Despite Net Loss

Harvard Bioscience, Inc. reported its financial results for the second quarter of 2026, revealing a revenue increase of 11.1% to $22.7 million, compared to $20.5 million in the same period last year. For the first half of 2026, revenues rose by 3.0% to $43.5 million, up from $42.2 million in the first half of 2025. The growth in revenue was primarily driven by increased sales to contract research organizations (CROs) and pharmaceutical companies across the Americas, Europe, and Asia, particularly in China. Despite the revenue growth, the company reported a net loss of $2.9 million for the second quarter, compared to a loss of $2.3 million in the prior year, and a total net loss of $6.3 million for the first half of 2026, an improvement from a loss of $52.6 million in the same period of 2025, which included a significant goodwill impairment charge.

The company’s gross profit for the second quarter increased by 9.5% to $12.6 million, resulting in a gross margin of 55.6%, slightly down from 56.4% in the previous year. The increase in gross profit was attributed to higher sales volumes, although the gross margin was impacted by an unfavorable product mix. Operating expenses rose, with sales and marketing expenses increasing by 19% to $5.4 million, driven by higher personnel and travel costs, while general and administrative expenses rose to $4.6 million. Research and development expenses also increased to $2.5 million, reflecting the normalization of costs.

In terms of strategic developments, Harvard Bioscience initiated "Project Viking," a comprehensive plan aimed at consolidating its manufacturing operations to enhance efficiency and support long-term growth. This initiative is expected to yield approximately $3 million in cost savings by 2027 and $4 million annually starting in 2028. The company also reported restructuring costs of $0.3 million in the second quarter related to this project. Additionally, the company is undergoing a restructuring of its sales, services, and marketing strategy, which is anticipated to generate further cost savings.

As of June 30, 2026, Harvard Bioscience's total assets were $76.3 million, down from $80.1 million at the end of 2025, primarily due to a decrease in cash and cash equivalents, which fell to $6.5 million from $8.6 million. The company’s total liabilities increased to $68.9 million, up from $66.3 million, largely due to an increase in accounts payable and long-term debt. The company’s employee headcount has also been adjusted as part of its restructuring efforts, although specific numbers were not disclosed.

Looking ahead, Harvard Bioscience remains focused on its strategic pillars, including enhancing its product portfolio and operational excellence. The company anticipates that ongoing economic uncertainties and market conditions may continue to impact its performance, particularly regarding customer purchasing behavior influenced by funding levels from government sources. The management expressed cautious optimism about future growth, contingent on the successful execution of its strategic initiatives and market recovery.